Corvidia

About

Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.

Waltham,Massachusetts,United States
11 - 50
http://corvidiatx.com/

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: $26M
Industries: Biotechnology,Genetics,Health Care,Medical,Therapeutics
Founded date: Jan 1, 2014
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: Corvidia Therapeutics, Inc.
Also Known As: Corvidia Therapeutics

Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

$86.82M

Corvidia has raised a total of $86.82M in funding over 2 rounds. Their latest funding was raised on Mar 24, 2020 from a Convertable Note round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Mar 24, 2020	Convertable Note	$827.33K	1	—	—	Detail
Apr 25, 2018	Series B	$60M	9	Venrock	—	Detail
Feb 17, 2016	Series A	$26M	2	Apple Tree Partners Sofinnova Partners	—	Detail

Investors

Number of Lead Investors

Number of Investors

3

9

Corvidia is funded by 9 investors. Venrock and HBM Healthcare Investments AG are the most recent investors.

Investor Name	Lead Investor	Funding Round
Venrock	Yes	Series B
HBM Healthcare Investments AG	—	Convertable Note
Andera Partners	—	Series B
Apple Tree Partners	—	Series B
Cormorant Asset Management	—	Series B
Fresenius Medical Care	—	Series B
MedImmune	—	Series B
Sofinnova Partners	—	Series B
Venrock Healthcare Capital Partners	—	Series B